Neuroblastoma Treatment Market Size, Share, Analysis, Growth Report 2032

Neuroblastoma Treatment Market Size

According to a report from Zion Market Research, the global Neuroblastoma Treatment Market was valued at USD 745.5 Million in 2023 and is projected to hit USD 1314 Million by 2032, with a compound annual growth rate (CAGR) of 6.5% during the forecast period 2024-2032.

This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Neuroblastoma Treatment Market industry over the next decade.

Request Free Sample

Neuroblastoma Treatment Market: Overview

Neuroblastoma is a type of pediatric cancer that is developed in the nervous system of babies and young children. It grows in immature nerve tissue known as neuroblasts. It affects the adrenal glands present just above the kidneys. Neuroblastoma can also develop in nerve tissue in the spinal cord, abdomen, chest, or neck. It can spread to other parts of the body. Due to the higher rate of neuroblastoma, the need for treatment is necessary for the coming years. The increasing population and frequency of this cancer is the prime reason for the treatment of Neuroblastoma and hence there is the growth rate for this market is necessary.

Request Free Sample

COVID-19 Impact Analysis

According to data gathered from countries such as UK & U.S. the treatment for neuroblastoma was on a halt as young children and babies get affected by coronavirus at a rapid rate. CCLG, one of the active groups of doctors in the UK has also recently published data about children with cancer who have had coronavirus, to provide a clear picture of the impact of the virus on young cancer patients. Based on the information gathered by this project, CCLG’s updated advice includes recommendations for the extremely vulnerable and vulnerable groups. Thus, the market for neuroblastoma was on a steady growth rate due to COVID-19.

Neuroblastoma Treatment Market: Growth Factors

Neuroblastoma is rare cancer but it’s the most common cancer in babies. According to a health organization in the United States, about 800 children are diagnosed with neuroblastoma. It almost always develops before age 5. It can occur in babies before they are born. Neuroblastoma is very rare in children over age 10.

There are four stages of neuroblastoma such as Stage L1, Stage L2, Stage M, and Stage MS. Neuroblastoma happens when immature nerve tissues (neuroblasts) grow out of control. The cells become abnormal and continue growing and dividing, forming a tumor. A genetic mutation (a change in the neuroblast’s genes) causes the cells to grow and divide uncontrollably.

Healthcare providers are not sure what causes the genetic mutation and still, there is no technology to find the main cause of this cancer to grow. Due to this reason, the need treatment is necessary and government bodies and healthcare companies are investing huge funds in research and development for this treatment. In coming years due to higher birthrate the need for this treatment is the major factor concerning the growth of the neuroblastoma treatment market.

Neuroblastoma Treatment Market: Segmentation

Therapy Segment Analysis Preview

The therapy segment is subdivided into Surgery, Chemotherapy, Immunotherapy, and Radiotherapy. The surgery segment is one of the major segments that contribute about 45% of total global revenue for the neuroblastoma treatment market, followed by other segments such as chemotherapy, immunotherapy, and radiotherapy. Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. A surgical oncologist is a doctor who specializes in treating cancer using surgery.

If the cancer has not spread, surgery can sometimes be used to remove the entire tumor. Chemotherapy is the use of drugs to destroy cancer cells, usually by ending the cancer cell's ability to grow and divide. Chemotherapy is given by a pediatric oncologist or a medical oncologist, a doctor who specializes in treating cancer with medication. Radiotherapy is the use of high-energy X-rays or other particles to destroy cancer cells.

Neuroblastoma Treatment Market: Report Scope

Neuroblastoma Treatment Market: Regional Analysis

North America dominated the market in 2023. The market growth is due to factors such as the high prevalence of neuroblastoma in the region, and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region, the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. According to the American Cancer Society’s Cancer Statistics, nearly 800 new cases of neuroblastoma are reported in the United States every year. The above statistics prove that the high prevalence of the disease is boosting the market in the region.

Neuroblastoma Treatment Market: Competitive Players

Major market players in Neuroblastoma Therapy Market are

• United Therapeutics Corporation
• Apeiron Biologics AG
• Baxter
• Cellectar Biosciences. Inc.
• Pfizer, Inc., MacroGenics. Inc.
• Bayer AG
• Sun Pharmaceutical Industries, Inc.
• Sartorius AG.

Brief information about 10 companies will also be provided in the report. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were a few techniques adopted by most of the companies providing the neuroblastoma therapy market in recent years. For instance, on June 23, 2021, Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of neuroblastoma cancer. The FDA-approved product DANYELZA is launched by the company which will benefit neuroblastoma patients.

The Neuroblastoma Therapy Market is segmented as follows:

By Therapy

• Surgery
• Chemotherapy
• Immunotherapy
• Radiotherapy

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa